{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:35:02Z","timestamp":1780515302376,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s10067-014-2507-4","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T03:52:29Z","timestamp":1391399549000},"page":"609-612","source":"Crossref","is-referenced-by-count":47,"title":["Abatacept as a successful therapy for myositis\u2014a case-based review"],"prefix":"10.1007","volume":"34","author":[{"given":"Anne M.","family":"Kerola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku J.","family":"Kauppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"2507_CR1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/BOR.0b013e328358ac72","volume":"24","author":"R Aggarwal","year":"2012","unstructured":"Aggarwal R, Oddis CV (2012) Therapeutic advances in myositis. Curr Opin Rheumatol 24:635\u2013641","journal-title":"Curr Opin Rheumatol"},{"key":"2507_CR2","doi-asserted-by":"crossref","unstructured":"Carstens PO, Schmidt J (2013) Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol.","DOI":"10.1111\/cei.12194"},{"key":"2507_CR3","doi-asserted-by":"crossref","unstructured":"Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 8:CD003643","DOI":"10.1002\/14651858.CD003643.pub4"},{"key":"2507_CR4","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","volume":"50","author":"M Couderc","year":"2011","unstructured":"Couderc M, Gottenberg JE, Mariette X et al (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford) 50:2283\u20132289","journal-title":"Rheumatology (Oxford)"},{"key":"2507_CR5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/RHU.0b013e3181bb8e70","volume":"15","author":"S Majmudar","year":"2009","unstructured":"Majmudar S, Hall HA, Zimmermann B (2009) Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 15:338\u2013340","journal-title":"J Clin Rheumatol"},{"key":"2507_CR6","first-page":"363","volume":"29","author":"FJ Garcia-Hernandez","year":"2011","unstructured":"Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, Sanchez-Roman J (2011) Rituximab is effective in the treatment of patients with idiopathic inflammatory myopathy. Clin Exp Rheumatol 29:363\u2013364","journal-title":"Clin Exp Rheumatol"},{"key":"2507_CR7","doi-asserted-by":"crossref","unstructured":"Basnayake C, Cash K, Blumbergs P, Limaye V (2013) Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol.","DOI":"10.1007\/s10067-013-2449-2"},{"key":"2507_CR8","first-page":"896","volume":"31","author":"F Munoz-Beamud","year":"2013","unstructured":"Munoz-Beamud F, Isenberg DA (2013) Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol 31:896\u2013903","journal-title":"Clin Exp Rheumatol"},{"key":"2507_CR9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324","journal-title":"Arthritis Rheum"},{"key":"2507_CR10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","volume":"70","author":"Muscle Study Group","year":"2011","unstructured":"Muscle Study Group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70:427\u2013436","journal-title":"Ann Neurol"},{"key":"2507_CR11","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","volume":"65","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65:1233\u20131236","journal-title":"Ann Rheum Dis"},{"key":"2507_CR12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/rheumatology\/keh539","volume":"44","author":"A Anandacoomarasamy","year":"2005","unstructured":"Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 44:562\u2013563","journal-title":"Rheumatology (Oxford)"},{"key":"2507_CR13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","volume":"50","author":"GJ Hengstman","year":"2003","unstructured":"Hengstman GJ, van den Hoogen FH, Barrera P et al (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50:10\u201315","journal-title":"Eur Neurol"},{"key":"2507_CR14","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi M, Grundtman C, Alexanderson H et al (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67:1670\u20131677","journal-title":"Ann Rheum Dis"},{"key":"2507_CR15","first-page":"1802","volume":"33","author":"F Iannone","year":"2006","unstructured":"Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33:1802\u20131804","journal-title":"J Rheumatol"},{"key":"2507_CR16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3899\/jrheum.120682","volume":"40","author":"IN Lazarou","year":"2013","unstructured":"Lazarou IN, Guerne PA (2013) Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 40:550\u2013564","journal-title":"J Rheumatol"},{"key":"2507_CR17","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","volume":"132","author":"MC Dalakas","year":"2009","unstructured":"Dalakas MC, Rakocevic G, Schmidt J et al (2009) Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132:1536\u20131544","journal-title":"Brain"},{"key":"2507_CR18","doi-asserted-by":"crossref","unstructured":"Zong M, Dorph C, Dastmalchi M et al. (2013) Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis.","DOI":"10.1136\/annrheumdis-2012-202857"},{"key":"2507_CR19","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/art.24689","volume":"60","author":"N Okiyama","year":"2009","unstructured":"Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H (2009) Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 60:2505\u20132512","journal-title":"Arthritis Rheum"},{"key":"2507_CR20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","volume":"50","author":"M Narazaki","year":"2011","unstructured":"Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T (2011) Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 50:1344\u20131346","journal-title":"Rheumatology (Oxford)"},{"key":"2507_CR21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs BW, Zhu W, Morehouse C et al (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73:256\u2013262","journal-title":"Ann Rheum Dis"},{"key":"2507_CR22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3899\/jrheum.120257","volume":"89","author":"F Iannone","year":"2012","unstructured":"Iannone F, Lapadula G (2012) The inhibitor of costimulation of T cells: abatacept. J Rheumatol Suppl 89:100\u2013102","journal-title":"J Rheumatol Suppl"},{"key":"2507_CR23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jbspin.2011.03.022","volume":"78","author":"JL Musuruana","year":"2011","unstructured":"Musuruana JL, Cavallasca JA (2011) Abatacept for treatment of refractory polymyositis. Joint Bone Spine 78:431\u2013432","journal-title":"Joint Bone Spine"},{"key":"2507_CR24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","volume":"160","author":"B Arabshahi","year":"2012","unstructured":"Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160:520\u2013522","journal-title":"J Pediatr"},{"key":"2507_CR25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0002-9440(10)65141-3","volume":"155","author":"K Murata","year":"1999","unstructured":"Murata K, Dalakas MC (1999) Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155:453\u2013460","journal-title":"Am J Pathol"},{"key":"2507_CR26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/clim.1999.4743","volume":"92","author":"K Nagaraju","year":"1999","unstructured":"Nagaraju K, Raben N, Villalba ML et al (1999) Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 92:161\u2013169","journal-title":"Clin Immunol"},{"key":"2507_CR27","unstructured":"the U.S. National Institutes of Health: ClinicalTrials.gov. Available at: www.clinicaltrials.gov . Accessed 23 Dec 2013"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2507-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2507-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2507-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T07:42:16Z","timestamp":1565163736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2507-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["2507"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2507-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]}}}